-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NaKx2sN1if2R7AdcR8J0VLtpoaQ4zfXwNsbxn6BrqgPrJu25oKGQPVtFrt8ShgON WEVG9iZ5qcw5bhdJLJBQsg== 0000109657-07-000015.txt : 20070713 0000109657-07-000015.hdr.sgml : 20070713 20070511165325 ACCESSION NUMBER: 0000109657-07-000015 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OXIS INTERNATIONAL INC CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 323 VINTAGE PARK DRIVE, SUITE B CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6502122568 MAIL ADDRESS: STREET 1: 323 VINTAGE PARK DRIVE, SUITE B CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 CORRESP 1 filename1.htm Correspondence
 

May 11, 2007

Filed as Correspondence Via EDGAR

Division of Corporate Finance
Securities and Exchange Commission
100 F. Street, N.E.
Washington, D.C. 20549
Attn: Gregory S. Belliston

RE:    OXIS International, Inc.
   Post-Effective Amendments to Form SB-2 Registration Statements
   Filed May 9, 2007
  (File Nos. 333-123008 and 333-139216)

Dear Mr. Belliston:

OXIS International, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (“Commission”) take appropriate action to make the above-captioned registration statement, as amended, be ordered effective as soon as practicable.

The Company acknowledges that:

1.  should the Commission or the staff, acting pursuant to delegated authority, declare the filings effective, it does not foreclose the Commission from taking any action with respect to the filings;

2.  the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filings effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filings; and

3.  the Company may not assert staff comments and the declaration of effectiveness as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

      Very truly yours,

      /s/ Marvin S. Hausman 
      Marvin S. Hausman
      CEO, OXIS International, Inc.


cc:  Edgar D. Park, Richardson & Patel
 -----END PRIVACY-ENHANCED MESSAGE-----